Holen Sie sich die Stockscreener-App
59.04
0.84%
-0.50
Handel nachbörslich:
59.04
Tarsus Pharmaceuticals Inc Aktie (TARS) Neueste Nachrichten
Tarsus Pharmaceuticals Inc (TARS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Midday Stock Roundup: Rivian Automotive Up on Piper Sandler Upgrade - Orange County Business Journal
Tarsus Pharmaceuticals Inc (TARS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tarsus Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:TARS - TradingView
Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching (TARS) - Seeking Alpha
Tarsus Pharmaceuticals Inc (TARS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Cash Flow - TradingKey
TradingKey - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Institutional Confidence - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tarsus Pharmaceuticals, Inc. (TARS) Options Chain - Yahoo! Finance Canada
TARS|Tarsus Pharmaceuticals Inc|Price:60.100|Chg%:+1.440 - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TARS Maintained by Guggenheim -- Price Target Lowered to $89.00 - GuruFocus
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $89 - Moomoo
How Tarsus Pharmaceuticals Inc. (TARS) Affects Rotational Strategy Timing - Stock Traders Daily
Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 By Investing.com - Investing.com Canada
Tarsus Pushes into Retinal Market in $75M Deal - Orange County Business Journal
Tarsus Pharmaceuticals commercial chief leaves company - MSN
Tarsus Pharmaceuticals (TARS) Replaces Its Commercial Chief While iRenix Talks Continue - Yahoo Finance
Tarsus acquires iRenix Medical, adds late-stage ocular antiseptic - Glance by Eyes On Eyecare
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH) and Tarsus Pharmaceuticals (TARS) - The Globe and Mail
Tarsus Pharmaceuticals Announces Executive Leadership Transition - VisionMonday.com
Tarsus Chief Commercial Officer Departs - Orange County Business Journal
Tarsus Pharmaceuticals acquires iRenix for $75 million upfront By Investing.com - Investing.com Nigeria
A Quick Look at Today's Ratings for Tarsus Pharmaceuticals(TARS.US), With a Forecast Between $90 to $100 - Moomoo
Tarsus Pharmaceuticals, Inc. Announces Management Changes, Effective July 13, 2026 - marketscreener.com
Tarsus Pharmaceuticals Announces Chief Commercial Officer Transition - TipRanks
Tarsus Pharmaceuticals Hits Day Low of $57.51 Amid Price Pressure - MarketsMojo
Tarsus Pharmaceuticals (TARS) Announces Departure of Chief Comme - GuruFocus
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth - The Manila Times
[8-K] Tarsus Pharmaceuticals, Inc. Reports Material Event - Stock Titan
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline - TradingView
William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating - Moomoo
Tarsus Pharmaceuticals Acquires iRenix Medical, Developer of Late-Stage Ocular Antiseptic IRX-101 - VisionMonday.com
All you need to know about Tarsus Pharmaceuticals (TARS) rating upgrade to buy - MSN
Tarsus Pharmaceuticals Acquires iRenix for $75M - Orange County Business Journal
TARS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $88 - GuruFocus
Tarsus Pharmaceuticals (TARS) Q3 2024 earnings summary - Quartr
Tarsus Pharmaceuticals (TARS) Slips 1.5% as Stock Holds Above Key SupportSector Neutral Pair - dars.gov.et
Tarsus Pharmaceuticals, Inc. (TARS) iRenix Medical, Inc.,M&A CallSlideshow (NASDAQ:TARS) 2026-07-09 - Seeking Alpha
Tarsus Pharmaceuticals (TARS) M&A announcement Summary - Quartr
Tarsus Pharmaceuticals (TARS) Acquires iRenix Medical for $75M - GuruFocus
Tarsus Pharmaceuticals acquires iRenix for $75 million upfront - Investing.com
Tarsus buys iRenix Medical for $75M, gains late-stage eye care asset IRX-101 - MSN
TARS Acquires iRenix Medical for $75M in a Strategic Move - GuruFocus
Tarsus Pharmaceuticals Buys IRenix Medical - Moomoo
Tarsus Pharmaceuticals Acquires iRenix With $37.5M Cash, Stock; Milestones Up to $490M - TradingView
Tarsus (NASDAQ: TARS) acquires iRenix, adds late-stage IRX-101 eye asset - Stock Titan
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101 - GlobeNewswire
All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy - Yahoo! Finance Canada
Tarsus pays $75M for eye drug candidate with Phase 3 ahead - Stock Titan
Tarsus Pharmaceuticals (TARS) Holds Steady Near Midpoint: Support and Resistance in FocusGap and Reverse - dars.gov.et
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Is Tarsus Pharmaceuticals (TARS) Undervalued Following Culper’s Short Report? - simplywall.st
Tarsus Pharmaceuticals (TARS) moves 7.5% higher: Will this strength last? - MSN
Tarsus Pharmaceuticals Q1 2026 Earnings: EPS Beat Drives 7.5% Share Gain Amid Pre-Revenue StageEarnings Outlook Update - DonanımHaber
Enterprise value to revenue forward of Tarsus Pharmaceuticals, Inc. – NASDAQ:TARS - TradingView
Price to earnings forward of Tarsus Pharmaceuticals, Inc. – NASDAQ:TARS - TradingView
Price to sales forward of Tarsus Pharmaceuticals, Inc. – NASDAQ:TARS - TradingView
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):